Compare Crescent Energy Company Class A Common Stock (CRGY) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crescent Energy Company Class A Common Stock vs Crispr Therapeutics AG — how do they compare? Crescent Energy Company Class A Common Stock trades at $12.7 (market cap $4.30B), while Crispr Therapeutics AG trades at $53.51 (market cap $4.88B). The key difference: Crescent Energy Company Class A Common Stock and Crispr Therapeutics AG are close in size by market cap, and Crescent Energy Company Class A Common Stock pays a 3.69% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crescent Energy Company Class A Common Stock for 1 Days and Crispr Therapeutics AG for 77 Days on average.
| CRGY | CRSP | |
|---|---|---|
Market Cap | $4.30B | $4.88B |
Volume | 15,201,625 | 2,861,747 |
Sector | Energy | Health |
52-Week High | $15.37 | $74.92 |
52-Week Low | $7.75 | $44.34 |
Typical Hold Time | 1 Days | 77 Days |
Enterprise Value | $9.31B | $3.30B |
Dividend Yield | 3.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crescent Energy Company Class A Common Stock
Crescent Energy acquires, develops, and produces oil and natural gas from onshore U.S. basins. Its portfolio includes producing assets with oil and natural gas exposure.
Read more on CRGY →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
